Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II trial of CEQ 508 for the prevention of colorectal cancer in patients with familial adenomatous polyposis.

Trial Profile

Phase II trial of CEQ 508 for the prevention of colorectal cancer in patients with familial adenomatous polyposis.

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 10 Jan 2012

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CEQ 508 (Primary)
  • Indications Colorectal cancer; Familial adenomatous polyposis
  • Focus Therapeutic Use
  • Sponsors Cequent Pharmaceuticals

Most Recent Events

  • 06 Jan 2012 Marina Biotech receives $US5 million in funds, which will in part aid in financing this trial, as reported in a company media release.
  • 16 Apr 2010 Cequent expects to initiate this trial in 2011, according to a company media release.
  • 16 Apr 2010 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top